Ambrx Stock Analysis

AMAM -  USA Stock  

USD 6.10  0.07  1.16%

The big decline in price over the last few months for Ambrx Biopharma could raise concerns from stakeholders as the firm it trading at a share price of 6.10 on very low momentum in volume. The company executives failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Ambrx Biopharma or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.02. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Ambrx Biopharma partners.
Please continue to Trending Equities.

Ambrx Stock Analysis 

 
Refresh
The Ambrx Biopharma stock analysis report makes it easy to digest most publicly released information about Ambrx Biopharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Ambrx Stock analysis module also helps to analyze the Ambrx Biopharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Ambrx Stock Analysis Notes

About 39.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.11. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ambrx Biopharma has Price/Earnings To Growth (PEG) ratio of 0.4. The entity recorded a loss per share of 4.97. The firm had not issued any dividends in recent years. Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics using its proprietary expanded genetic code technology platform. The company was founded in 2003 and is based in La Jolla, California. Ambrx Biopharma operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 70 people. For more info on Ambrx Biopharma please contact the company at 858 875 2400 or go to https://ambrx.com.

Ambrx Biopharma Quarterly Deferred Revenue

6.07 MillionShare

Ambrx Biopharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ambrx Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ambrx Biopharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Ambrx Biopharma generated a negative expected return over the last 90 days
Ambrx Biopharma has high historical volatility and very poor performance
The company reported the previous year's revenue of 12.32 M. Net Loss for the year was (40.12 M) with profit before overhead, payroll, taxes, and interest of 13.67 M.
Ambrx Biopharma currently holds about 167.2 M in cash with (39.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.78.
Ambrx Biopharma has a very weak financial position based on the latest SEC disclosures
Latest headline from www.nasdaq.com: Delta Air Lines Beats on Q4 Earnings, Warns of Q1 Loss - Nasdaq

Ambrx Biopharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Ambrx Biopharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Ambrx Biopharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Ambrx Biopharma specific information freely available to individual and institutional investors to make a timely investment decision.
4th of January 2022
Other Events
View
9th of December 2021
Other Events
View
22nd of November 2021
Other Events
View
8th of November 2021
Other Events
View
28th of October 2021
Other Events
View
4th of October 2021
Other Events
View
12th of July 2021
Unclassified Corporate Event
View
2nd of July 2021
Other Events. Unclassified Corporate Event
View

Ambrx Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 213.23 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ambrx Biopharma's market, we take the total number of its shares issued and multiply it by Ambrx Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Ambrx Profitablity

Ambrx Biopharma's profitability indicators refer to fundamental financial ratios that showcase Ambrx Biopharma's ability to generate income relative to its revenue or operating costs. If, let's say, Ambrx Biopharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Ambrx Biopharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Ambrx Biopharma's profitability requires more research than a typical breakdown of Ambrx Biopharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.15) (0.16) 
Return on Average Equity 0.28  0.28 
Return on Invested Capital 4.10  4.07 
Return on Sales(1.39) (1.50) 

Management Efficiency

The entity has return on total asset (ROA) of (8.38) % which means that it has lost $8.38 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (23.65) %, meaning that it created substantial loss on money invested by shareholders. Ambrx Biopharma management efficiency ratios could be used to measure how well ambrx biopharma manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to pull down to -0.16. The value of Return on Invested Capital is expected to pull down to 4.07. Ambrx Biopharma Assets Non Current are relatively stable at the moment as compared to the past year. The company's current value of Assets Non Current is estimated at 37.19 Million. Goodwill and Intangible Assets is expected to hike to about 33.3 M this year, although the value of Total Assets will most likely fall to nearly 137.8 M.
Last ReportedProjected for 2022
Book Value per Share(7.59) (7.79) 
Tangible Assets Book Value per Share 6.76  5.61 
Tangible Asset Value111.8 M93.7 M

Technical Drivers

As of the 17th of January 2022, Ambrx Biopharma shows the risk adjusted performance of (0.11), and Mean Deviation of 3.84. Ambrx Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Ambrx Biopharma, which can be compared to its rivals. Please confirm Ambrx Biopharma information ratio, and the relationship between the downside deviation and value at risk to decide if Ambrx Biopharma is priced correctly, providing market reflects its regular price of 6.1 per share. Given that Ambrx Biopharma has jensen alpha of (0.84), we suggest you to validate Ambrx Biopharma's prevailing market performance to make sure the company can sustain itself at a future point.

Ambrx Biopharma Price Movement Analysis

The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Ambrx Biopharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Ambrx Biopharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Ambrx Biopharma Technical and Predictive Indicators

Ambrx Biopharma Forecast Models

Ambrx Biopharma time-series forecasting models is one of many Ambrx Biopharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ambrx Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Ambrx Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Ambrx Biopharma stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ambrx shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Ambrx Biopharma. By using and applying Ambrx Stock analysis, traders can create a robust methodology for identifying Ambrx entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(1.10) (1.19) 
Gross Margin 0.90  0.89 
Profit Margin(1.39) (1.50) 
Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics using its proprietary expanded genetic code technology platform. The company was founded in 2003 and is based in La Jolla, California. Ambrx Biopharma operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 70 people.

Current Ambrx Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ambrx analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ambrx analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
28.0Strong Buy1Odds
Ambrx Biopharma current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Ambrx analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ambrx stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ambrx Biopharma, talking to its executives and customers, or listening to Ambrx conference calls.
Ambrx Analyst Advice Details

Ambrx Stock Analysis Indicators

Ambrx Biopharma stock analysis indicators help investors evaluate how Ambrx Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ambrx Biopharma shares will generate the highest return on investment. By understating and applying Ambrx Biopharma stock analysis, traders can identify Ambrx Biopharma position entry and exit signals to maximize returns.
Quick Ratio9.61
Fifty Two Week Low5.18
Revenue Growth-20.80%
Shares Short Prior Month3.05k
Average Daily Volume Last 10 Day28.93k
Average Daily Volume In Three Month17.84k
Shares Percent Shares Out0.01%
Gross Margins100.00%
Forward Price Earnings-14.88
Float Shares14.05M
Fifty Two Week High22.87
Enterprise Value To Ebitda-1.51
Fifty Day Average9.72
Two Hundred Day Average14.26
Enterprise Value To Revenue3.73
Please continue to Trending Equities. Note that the Ambrx Biopharma information on this page should be used as a complementary analysis to other Ambrx Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Ambrx Stock analysis

When running Ambrx Biopharma price analysis, check to measure Ambrx Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ambrx Biopharma is operating at the current time. Most of Ambrx Biopharma's value examination focuses on studying past and present price action to predict the probability of Ambrx Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Ambrx Biopharma's price. Additionally, you may evaluate how the addition of Ambrx Biopharma to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Is Ambrx Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ambrx Biopharma. If investors know Ambrx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ambrx Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ambrx Biopharma is measured differently than its book value, which is the value of Ambrx that is recorded on the company's balance sheet. Investors also form their own opinion of Ambrx Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Ambrx Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ambrx Biopharma's market value can be influenced by many factors that don't directly affect Ambrx Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ambrx Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Ambrx Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ambrx Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.